AOD-9604 Nasal Spray
The tyrosine-led 16-residue growth hormone fragment, 10 mg as a sterile solution in bacteriostatic water in a metered spray bottle. Made from a peptide lot tested in the manufacturer’s own laboratory, with a certificate.
| Compound | AOD-9604 Tyr-hGH(177–191); lipolytic C-terminal fragment of human growth hormone |
|---|---|
| CAS number | 221231-10-3 |
| Molecular formula | C78H123N23O23S2 |
| Theoretical mass | 1815.1 Da |
| Sequence / structure | H-YLRIVQCRSVEGSCGF-OH (16 residues; Cys7–Cys14 disulfide; free N- and C-termini) |
| Contents | AOD-9604: 10 mg per bottle (≤ 0.1% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Format | Solution in a metered nasal spray bottle |
Sizes and lots
- 10 mg · 1 bottle — $118.99
- 10 mg · Kit of 10 — $1057.82
AOD-9604 is a modified C-terminal fragment of human growth hormone, sixteen residues long: hormone residues 177 to 191 with a tyrosine added at the N-terminus, and one disulfide ring. This listing supplies 10 mg of it as a sterile solution in bacteriostatic water, in a metered nasal spray bottle. Published work on AOD-9604 concerns fat metabolism and glucose control in obese rodents, and none of the studies cited here looked at the nasal route.
What is in the bottle
The bottle holds 10 mg of AOD-9604 dissolved in bacteriostatic water with 0.9% benzyl alcohol as a preservative. The safety data sheet puts the peptide at no more than 0.1% w/v, and the label states the exact concentration. Benzyl alcohol carries hazard statements for harm if swallowed or inhaled, serious eye irritation and skin sensitisation, while the peptide is not classified. Store the bottle upright and capped at 2 to 8 °C, away from light, and do not freeze it. General guidance on peptide solutions is in peptide storage and stability. The same peptide is sold freeze-dried in the AOD-9604 5 mg vial.
What the research covers
The C-terminal region of growth hormone was first studied as a source of metabolic activity in the 1970s. In normal rats, Ng and Bornstein found that synthetic fragments ending at residue 191 and starting at 172, 176, 177 or 178 produced a brief rise in blood glucose and a longer rise in insulin, and they concluded that active peptides needed the right physical configuration as well as the minimum sequence1. AOD-9604 came later, presented by Ng and colleagues as a synthetic version of growth hormone's lipolytic domain2. Over 19 days of oral treatment, obese Zucker rats gained less than half the weight of controls and showed more lipolytic activity in adipose tissue, with no adverse effect on insulin sensitivity, in contrast to chronic treatment with intact growth hormone2.
AOD-9604 keeps its two cysteines in a disulfide ring. Hogg reviewed evidence that some disulfide bonds work as switches, with cleavage changing what a secreted protein or receptor does3. None of the AOD-9604 papers cited here compared the closed ring with an open form, so it is not known whether the ring is needed for activity.
Frequently asked questions
How much AOD-9604 is in the bottle?
10 mg, according to the safety data sheet, at no more than 0.1% w/v; the label on the bottle gives the exact concentration. Where a study calls for a concentration chosen in the lab, the 5 mg vial supplies dry peptide of stated mass instead.
Has AOD-9604 been studied as a nasal spray?
Not in the papers cited on this page. The rodent studies gave the peptide by mouth or through implanted pumps, and the developer's human trials used tablets, so there are no published nasal findings to point to.
Why keep the spray cold and upright?
Those are the safety data sheet conditions: 2 to 8 °C, out of the light, upright, capped and never frozen. The certificate covers the peptide lot used to fill the bottle rather than the finished solution, so storage is the main control on the solution's condition.
References
- Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6. DOI · PubMed
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. DOI · PubMed
- Hogg PJ. Disulfide bonds as switches for protein function. Trends Biochem Sci. 2003;28(4):210-4. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.